Vaccine Technology VIII

An ECI Conference Series


June 12-17, 2022
Sitges, Spain

Melia Stiges Hotel

About This Conference

Vaccine Technology is the leading conference focused on the discovery, development and manufacture of vaccines. It brings together internationally leading experts to discuss the technologies and discoveries that have advanced vaccines for global needs.  

The meeting content is organized by scientists from academia and industry and differentiates itself from commercial conferences by providing very high quality, cutting-edge scientific content.  The conference welcomes presentations from both academia and industry and will have dedicated sessions.

Conference Organization

Tarit Mukhopadhyay, Merck Research Laboratories, USA
Charles Lutsch, Sanofi Pasteur
Linda Hwee-Lin Lua, University of Queensland
Francesc Godia, Universitat Autònoma de Barcelona

Program at a Glance

Keynote and Lead Speakers

Keynote Speakers

Alexander (Sandy) Douglas, University of Oxford

Alexander Douglas
Alexander Douglas

Sandy trained clinically as a pharmaceutical physician. He leads a research group at the University of Oxford with interests in vaccine manufacturing and in translational development of novel vaccines, including against rabies.

He and his team developed the core of the process used to make the Oxford / AstraZeneca COVID-19 vaccine at large scale, and the model of internationally distributed manufacturing of the product using multiple existing facilities. Before AZ’s involvement in the programme, he established the CDMO consortium which scaled up production in the UK, and initiated technology transfer to major Indian & Chinese manufacturers. He has subsequently continued to work closely with AZ.

Sarah Gilbert works on vaccines for many different emerging pathogens, including influenza, Nipah, MERS, Lassa, Crimean-Congo haemorrhagic fever, and in 2020, she initiated the SARS-CoV-2 vaccine project. Working with Oxford colleagues she is able to take novel vaccines from design to clinical development, with a particular interest in the rapid transfer of vaccines into manufacturing and first in human trials. She is the Oxford Project Leader for ChAdOx1 nCoV-19.

Sarah Gilbert, Oxford

Sarah Gilbert

Sarah Gilbert works on vaccines for many different emerging pathogens, including influenza, Nipah, MERS, Lassa, Crimean-Congo haemorrhagic fever, and in 2020, she initiated the SARS-CoV-2 vaccine project. Working with Oxford colleagues she is able to take novel vaccines from design to clinical development, with a particular interest in the rapid transfer of vaccines into manufacturing and first in human trials. She is the Oxford Project Leader for ChAdOx1 nCoV-19.

Kathrin Jansen, Pfizer Inc.

Kathrin Jansen
Kathrin Jansen

Kathrin Jansen, Ph.D., is the Senior Vice President and Head of Vaccine Research and Development (VRD) at Pfizer Inc.  With over 28 years of pharmaceutical experience in Vaccine R&D. Dr. Jansen leads a fully integrated, global vaccines research and development organization. She manages a clinical vaccines portfolio that includes vaccines to prevent or treat diseases of significant unmet medical need such as those caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Streptococcus pneumoniae, Clostridioides difficile, Respiratory syncytial virus, Group B streptococcus, and Lyme disease. In collaboration with BioNTech, Dr. Jansen led the development of the BNT162b2 vaccine candidate against coronavirus disease 2019 (Covid-19). The vaccine was issued the first emergency use authorization (EUA) by the U.S. Food and Drug Administration – less than 11 months after the he SARS-CoV-2 genetic sequence was released and the first-ever authorized vaccine utilizing an mRNA platform.

Jean-Marie Okwo-Bele, WHO

Jean-Marie Okwo-Bele

Dr. Jean-Marie Okwo-Bele has been Director of the WHO Department of Immunization, Vaccines and Biologicals since 2004.  He is responsible for strategic direction, coordination and management of normative and programmatic immunization activities

David Robinson, BMGF

David Robinson

David Robinson joined the Bill & Melinda Gates Foundation in 2017 as deputy director, CMC Vaccines Development and Surveillance.  He and his team work with internal and external partners to develop and execute CMC strategies ad harness advances in science and technology that enable vaccine development to save lives in developing countries.

Lead Speakers

Dr. Isabelle Bekeredjan-Ding, Paul-Ehrlich-Institut

H:\Persönlich\Photos 2018\Isabelle Bekeredjian1.jpg
Dr. Isabelle Bekeredjan-Ding

Isabelle Bekeredjian-Ding is the Head of the Microbiology Division at the Paul-Ehrlich-Institut. She is a Medical Microbiologist and Immunologist and Associate Professor at the University of Bonn, Germany. She received her Medical School training at the University of Heidelberg, Padova (Italy) and Mt. Sinai in New York and the clinical training in Munich and Heidelberg. After a PhD equivalent in T cell and a postdoc in dendritic cell biology her research interest focused on immune recognition of infectious pathogens and microbiological methods. Before joining PEI she was deputy director of the Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany. Her current offices include Chair of the Innovative Medicines Initiative (IMI2 JU) Scientific Committee, CHMP Vaccines Working Party Member at the EMA and Lead of the Blood Working Group Subgroup for Infectious Pathogens of the German Ministry of Health.

Dr. Christian Brander, Universitat de Vic

S:\CONF\20 Confs\20-AA Vaccine\Web Information\Brander pic ICREA .jpg
Dr. Christian Brander

Christian Brander graduated from the University of Bern in 1994 with a PhD in immunology studying exogenous antigen re-presentation on HLA class I molecules and Tcell hyperreactivity reactions to Penicillin. He then spent 13 years at Harvard University focusing on cellular immunity to viral infections and the impact that host genetics have on this immune response. He joined ICREA in 2008 with an appointment at the IrsiCaixa AIDS Research Institute to continue his work on host genetics and the cellular immunity to viral infections, including HIV, HCV and herpesviruses such as KSHV and EBV. He is the curator of the Los Alamos HIV Immunology database and the scientific director of the HIVACAT program, a project for the development of effective preventive and therapeutic HIV vaccines.

Dr. Brander’s current work focuses on the cellular immunity to viral infections in the immune compromised host.

Dr. Nicolas Havelange, CMC and Project Manager Consultant at CEPI

S:\CONF\20 Confs\20-AA Vaccine\Web Information\Bio-Photo-Havelange.jpg
Dr. Nicolas Havelange

Nicolas, a chemical and biotechnology engineer has more than 20 years of experience in the chemistry and biotechnology industries, with a specific focus on biomanufacturing and vaccines. He held diverse positions (i.e. process development, manufacturing, business development) at SmithKline Beecham Biologicals (now GSK Vaccines), Henogen (now Novasep-Henogen), Artelis/ATMI (now Pall LifeSciences), European Vaccine Initiative and CuraVac. Nicolas holds a Master in Chemical Engineering from Ecole Polytechnique de l’Université Libre de Bruxelles (ULB) and a Master in Molecular Biology and Biotechnology also from ULB.

Dr. Mariagrazia Pizza, GSK Vaccines

S:\CONF\20 Confs\20-AA Vaccine\Web Information\Pizza pic.png
Dr. Mariagrazia Pizza

Prof. Mariagrazia Pizza received her degree in Chemistry and Pharmaceutical Technologies at the University of Naples, Italy. After a fellowship at the EMBO laboratories in Heidelberg, Germany, Mariagrazia moved to Siena, where she is currently Senior Scientific Director for Bacterial Vaccines at GSK Vaccines. She has led many bacterial projects and contributed to the discovery of a pertussis vaccine based on a genetically detoxified toxin, shown to be able to protect children from disease and to the discovery of new vaccine antigens by genome mining (reverse vaccinology), which are the basis of a new MenB vaccine now licensed in more than 38 countries worldwide. She has received many scientific awards, is fellow of Academic Societies and EMBO, and Honorary Visiting Professor at the University of Leicester. She has over 200 publications in international peer-reviewed journals and is co-inventor of many patents.

Dr. David B. Volkin

David Volkin
David Volkin

Dr. David B. Volkin is the Ronald T. Borchardt Distinguished Professor of Pharmaceutical Chemistry, and co-founder of the Vaccine Analytics and Formulation Center (VAFC) at The University of Kansas. The VAFC collaborates with global partners (non-profits, biopharma/vaccine companies, and academia) on analytical characterization and formulation development projects to facilitate novel vaccine and biotherapeutic drug candidates entering clinical trials, with a particular emphasis on lower-cost dosage forms for use in the developing world. 

Dr. Volkin joined the KU faculty in 2010 after a 20-year industry career in vaccine and biopharmaceutical R&D, including senior director positions at Merck Research Laboratories (Merck & Co.) and Centocor R&D (Johnson & Johnson). He led formulation and analytical groups that brought dozens of candidates into clinical trials, including five vaccines and three monoclonal antibodies approved for commercial use by regulatory agencies worldwide. Dr. Volkin graduated with B.A. in Chemistry from the University of California-San Diego and earned a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology. He is co-author of ~175 scientific publications and co-inventor on 15 U.S. patents including patents and papers describing the formulation and stabilization of the commercial HPV (Gardasil™) and rotavirus (RotaTeq™) vaccines. Dr. Volkin was awarded the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Award in Biotechnology in 2015.

Dr. Leor Weinberger, University of California, San Francisco

S:\CONF\20 Confs\20-AA Vaccine\Web Information\Headshot Leor Beard.jpg
Dr. Leor Weinberger

Leor Weinberger is currently Bowes Distinguished Professor, Director of the Gladstone/UCSF Center for Cell Circuitry, and Professor of Pharmaceutical Chemistry and Biochemistry & Biophysics at University of California, San Francisco. Weinberger obtained his Ph.D. in Biophysics from UC Berkeley in 2004 as an HHMI pre-doctoral fellow and was then a Lewis-Thomas Fellow at Princeton University. As a graduate student, Weinberger pioneered the study of the HIV decision-making circuit and provided the first experimental demonstration that stochastic fluctuations (‘noise’) in gene expression can regulate cell-fate decisions. His lab at Gladstone/UCSF has built off this work, discovering regulatory principles of virus-cell circuitry using mathematical and experimental approaches, and engineering first in-class resistance-proof antiviral therapies. Weinberger was named a Pew Scholar in 2008 and has been awarded the Alfred P. Sloan Research Fellowship, the W.M. Keck Research-Excellence Award, and the Bill and Melinda Gates Grand Challenges in Global Health Award.  In 2016, he was named a Blavatnik Scholar. He is the only individual ever to receive the NIH Director’s Pioneer Award, the NIH Avant-Garde Award, and the NIH Director’s New Innovator Award.

Program Outline

Session Descriptions

Sessions 1 and 2: Technological and clinical advances in vaccinology

Session Chairs (Session 1): 
Florian Krammer (Icahn School of Medicine at Mount Sinai, USA)
Julia Blanco (IRSI Caixa, Spain)

Session Chairs (Session 2):
Sandy Douglas (University of Oxford, UK)
Barry Buckland (BioLogicB, USA)

Our understanding of both the immune system and the molecular biology of pathogens enable new strategies for prevention and treatment. Advances in synthetic biology, antigen design, therapeutic vaccines, and specific immune modulation are examples that will play prominent roles for the vaccinology of the 21st century. Coupled with this are the clinical needs to consider the appropriate animal models and correlates of protection for specific disease targets to give early read outs for novel candidates. With a systems vaccinology approach, it may become possible to direct antibody and T-cell mediated responses and increase our understanding of the range of response. This session is dedicated to recent advances in vaccinology that promise to improve efficacy, safety and availability of “next generation” vaccines. 

Session 3: Next generation platforms

Session Chairs:
Amine Kamen (McGil University, Canada)
Fu Tong-Ming (Sanofi Pasteur, USA)

The need to accommodate the incredible diversity of vaccine targets in a reproducible, consistent, and cost-effective manner requires the development of platform technologies. The increasing use of automation, data rich experimentation and standardized design means that it is now possible to create platform technologies for the design of antigens, rapid expression technologies to further their testing, development and manufacture. The advantages of the platform approach should enable faster development times, predictable cost of goods and de-risked scale-up or scale-out opportunities. Specific examples and case studies will be sought for this session that typify the potential of next generation platforms. 

Sessions 4 and 5: Bioprocessing advances in vaccine development and manufacture

Session Chairs (Session 4):
Martina Micheletti (University College London, UK) 
Paula Alves (IBET, Portugal)

Session Chairs (Session 5):
Yvonne Genzel (Max Planck Institute Magdeburg, Germany) 
Joseph Joyce (Merck & Co., USA)

The development and manufacture of vaccines often requires significant understanding of the upstream production conditions and downstream purification requirements of the antigen, such that each new antigen and vaccine target presents a novel and unique challenge. Advancing bioprocessing often requires better understanding of the experimental space which can be achieved through the implementation of high throughput methodologies, machine learning, quality by design approaches and the creation of novel unit operations that can increase the quality and productivity of the process. This session is dedicated to the advances made in bioprocessing for vaccine development and manufacture.  

Sessions 6 and 7: Vaccine Analytics

Session Chairs (Session 6):
Isabelle Knott (GlaxoSmithKline, UK)
Paula Lei (NIH/VRC, USA) 

Session Chairs (Session 7):
Laura Palomares (UNAM, Mexico)
Sylvie Uhlrich (Sanofi Pasteur)

It encompasses all in vitro and in vivo assays to evaluate the biological, chemical and physical properties of a vaccine. In-depth characterization of vaccines provides an understanding on the function, potency and toxicity issues, and improves vaccine efficacy and safety. In addition, bio-analytical characterization plays a critical role in establishing comparability of the product produced with process, scale and site changes. 

Session 8: One World, One Health

Session Chairs:
Diego Fontana (Universidad Nacional Del Litoral, Argentina)
Jean-Christophe Audonnet (Boehringer-Ingelheim, France)

The vast majority of emerging and re-emerging pathogens in humans is of animal origin. Most of this growing number of threats has its origin in wildlife, while humans are exposed either directly or through indirect domestic animal contacts. Effective and economical ways of protecting mankind from emerging diseases are best based on combatting zoonotic pathogens at the animal source. The “One Health” concept creates awareness of the major opportunities that exist to protect public health through policies aimed at controlling these pathogens at the level of their animal hosts, or more specifically, at the interface between humans, animals and their environments. Implementation of these policies places those who have regular contacts with domestic animals, like owners, handlers and veterinarians, in the front line together with those who regularly come into contact with wildlife and their environment. This session will highlight the importance of the integration between medical and veterinary disciplines within the One Health concept. 

Session 9: Formulation and Delivery 

Session Chairs: 
Qinjian Zhao (Xiamen University, China)
Lakshmi Khandke (PATH Center for Vaccine Innovation and Access, USA)

This session highlights the different steps that need to be taken in order to bring a concept to the first clinical trial, from the definition of the vaccine form (formulation, route of administration) to the various steps that need to be taken before entering into humans. Each vaccine candidate is unique and will require specific approach, nonetheless a common path can be defined and followed to maximize the chances of reaching a fast go/no go decision. Those paths will be discussed, including from how to select the formulation and validate its choice, to discussing the new emerging delivery and adjuvant technologies that are being brought to the field of vaccines. 

Session 10: Capacity building and intervention for emerging and reemerging infectious diseases

Session Chairs: 
Martin Elsenhawer (WHO)
Matthew Downham (CEPI, UK)

Infectious diseases remain one of the two leading causes of global mortality. It is estimated that hundreds of thousand pathogens remain to be discovered and recent outbreaks including SARS, Ebola and Zika reveal major gaps in emergency response plans.  Initiatives, such as the Coalition for Epidemic Preparedness Innovations (CEPI) have been created to build on the global consensus that new and sustainable partnership models are needed to develop vaccines, diagnostics, and therapeutics to contain outbreaks of emerging and reemerging infectious diseases. Such partnerships should fill need for coordinated and proactive R&D and increased funding, stronger advanced development and manufacturing capabilities, regulatory innovations and harmonization of regulatory requirements. This session will provide a forum to highlight case studies on the accelerated development of new vaccines against emerging pathogens, and share views on novel strategies in building capacities to improve preparedness against emerging and reemerging infectious diseases. 

Vaccine Technology © Conferences History

Vaccine Technology I (2006)
Barry C. Buckland, John G. Aunins, Emilio A. Emini, and Jerald C. Sadoff 
Puerto Vallarta, Mexico

Vaccine Technology II (2008)
Barry C. Buckland, John G. Aunins, Paula Marques Alves, and Kathrin Jansen
Albufeira, Algarve, Portugal

Vaccine Technology III (2010)
Barry C. Buckland, John G. Aunins, Paula Marques Alves, and Kathrin Jansen
Nuevo Vallarta, Mexico

Vaccine Technology IV (2012)
Barry C. Buckland, John G. Aunins, Paula Marques Alves, and Kathrin Jansen
Albufeira, Algarve, Portugal

Vaccine Technology V (2014)
Laura Palomares, Manon Cox, John Aunins and Kathrin Jansen
Playa del Carmen, Mexico

Vaccine Technology VI (2016)
Laura Palomares, Tarit Mukhopadhyay, Manon Cox and Nathalie Garçon
Albufeira, Portugal

Vaccine Technology VII (2018)
Amine Kamen, Tarit Mukhopadhyay, Charles Lutsch, Nathalie Garcon
Mont Tremblant, Quebec, Canada

Call for Abstracts

Descriptions of the Sessions  You may pick one or two sessions that you feel your work fits best.

  • Abstract deadline is January 15, 2022.
  • Deadline for Poster Abstracts: January 15, 2022.

Please prepare your abstract according to this template:

All abstracts should be submitted electronically HERE.

Only a limited number of oral presentation slots are available and thus all submissions for oral sessions will be considered for both oral and poster presentation.

Conference Fees

Conference fees will be announced in January 2022.

Venue Information

Melia Stiges Hotel

Conveniently located in a quiet area of Sitges, the Melia Sitges Hotel is just 3 minutes’ walk from Balmins and Aiguadolç beaches. It offers a spa, a stylish garden with an outdoor pool, and a restaurant with a terrace. The Meliá Sitges is 5 minutes’ walk from Aiguadolç Marina and 10 minutes’ walk from the lively and historic town center. It is a 20-minute walk to the train station, which connects you with central Barcelona in just 40 minutes. The air-conditioned rooms at the Meliá feature modern, minimalist decor.
Each one has a pillow menu and a flat-screen TV with satellite channels. Available for a surcharge, the hotel’s YHI spa includes a gym, hydromassage pool, sauna and steam bath. Massage treatments are also available. The Bistrot Saffron restaurant serves modern Mediterranean food. There is also a stylish cocktail bar with seating in the garden.

Sitges, Spain
Sitges is a coastal town in Spain’s Catalonia region, about 35 km southwest of Barcelona, backed by the mountainous Parc Natural del Garraf. It is known for its Mediterranean beaches and seafront promenade lined with grand mansions. A seaside town, Sitges boasts some beautiful beaches right
on its doorstep. There are some 13 individually named beaches along a 2.5km promenade. It has been referred to as the Saint-Tropez of Spain and the Jewel of the Mediterranean. The compact old town and surrounding streets are filled with shops, restaurants, and many nightspots. Sitges is about a 20-minute drive from Barcelona’s El Prat international airport. It is not necessary to hire a car when staying in Sitges as there are excellent transport links to and from Barcelona airport and into Barcelona city. For those who wish to spend some time in Barcelona either prior to or after
the conference, Barcelona is easily accessible both by train and bus. The region can also be accessed from Reus and Girona airports with low cost airlines flying from many European airports.

The Maricel Museum and Cau Ferrat Museum showcase Catalan and other Spanish art. The Cau Ferrat building was once the home of Catalan artist Santiago Rusiñol, one of the leading figures of the Catalan Modernist movement. Upon his death, the artist bequeathed the house and its contents
– including drawings, paintings, ceramics and more – to the town of Sitges on condition that it be opened to the public as a museum. If the Old Town of Sitges is not particularly large, it is nonetheless worth exploring, in particular the old fishermen’s neighborhood and its white houses with blue borders, as well as the 15th-century Church of Sant Bartomeu and Santa Tecla and its Baroque interior. Sitges Old Town has typically Spanish narrow streets leading down to a palm tree lined promenade that runs along an open bay with its many beaches. A wide pedestrian boulevard stretching along the waterfront, the Passeig Maritim is one of the most
scenic walks to be enjoyed in Sitges. The walkway is lined with cafés, restaurants and ice cream shops. The proximity to the sea is reflected in the cuisine of Sitges’ well-regarded traditional restaurants, which can be found along the waterfront and in the Old Town. The gastronomy of Catalonia is rich and varied. Principally it is the typical Mediterranean diet of fish and seafood with fresh vegetables, olives and olive oil rice and pasta. Restaurants such as La Nansa and El Trull come highly recommended for their fresh fish as well as their hearty seafood rice dishes. The town has been built on an industry of fishing, commerce and wine, and has been much favored by artists, the bohemian crowd and more recently has developed a large gay community. If most people associate Bacardí Rum with Cuba, what they ignore is that the story actually begins in
Spain – and more precisely Sitges – where founder Facundo Bacardí Massó was born in 1814.

Today the Casa Bacardí talks of the brand’s heritage and the process of making rum, as well as offering the guests to try some rather delicious cocktails in the bar at the back. Sitges is a maritime town. It has a large tourist infrastructure and facilities. With three local marinas,
it has more than any other town in Spain. In addition to tourism, there are fishing, shoe-making, and artistic businesses, though the former now consist of smaller workshops. The town was rebuilt in the last century, to accommodate increased tourism. Noted for its outstanding location, the Church of Sant Bartomeu i Santa Tecla, better known as “La Punta” at the end of the promenade in a bastion above steps and a coastal cliff, has become one of the most recognized icons in Sitges, much photographed and painted. Its structure is quite peculiar, because it has two bell towers, and
possesses one of the watch towers that served the population to calculate the time. Its facade is quite simple but the frame where it is located is incomparable. The beautiful parish of San Bartolome and Santa Tecla is certainly the image that symbolizes Sitges. The church, built in the seventeenth century but with many subsequent amendments, is a charming Baroque style and the interior retains several Renaissance and Baroque altars and an organ of 1690.

The word Sitges means “silo” in English and it refers to the underground holes used to store wine. Before the tourist and LGBT boom of the 60s and 70s, Sitges was a wine producing fishing village big in shoemaking and with a thriving artistic and cultural scene. The name was given by the Sitges
family who took over the town in the 12th century. However, the town’s history dates back to thousands of years ago, from the Neanderthal period when it is believed that humans inhabited the caves at either end of the town. A Neanderthal jaw found in the Cova del Gegant in the 1950’s dates
back to 53,200 years ago and is one of the oldest human remains in Catalunya. When the Spanish Civil War started, Sitges, like the rest of Catalunya, entered a dark period when all the artistic appeal and openness of the city was stopped and went into hibernation until the second half of the 20th century when things started to improve. By the 60s and 70s, especially after Franco’s death, 75% of the population had moved from shoe making to tourism and most of the now famous festivals and cultural events that make the town proud and known were launched. After Franco’s death in 1975 and the arrival of democracy, Sitges experienced a renewed boom. And the world famous Sitges Carnival, banned during the dictatorship, was re-established.

Transportation to Sitges

By plane: The closest airports to Sitges are the airports of Barcelona, Spain.  The main international airport is Barcelona El-Prat Airport, served by most large international carriers.  Guidelines regarding metro, train and bus connections to the city of Barcelona are available in detail on the website of Barcelona El-Prat Airport. You may use this information in combination with the train timetables from the Spanish Railways official website.

Low-cost international carriers and other seasonal international carriers serve two smaller airports that are each approximately 100 km from Barcelona: Giona-Costa Brava Airport  and Raus Airport. From both these airports you can reach Sitges (or Barcelona) by special bus services.  If you are deciding whether to fly into Barcelona, Reus or Girona airports, it is worth considering all costs.  If you find thata flight to Reus or Girona is cheaper than one to Barcelona Airport, make sure that you add up the other costs of further travel before booking your ticket.

By train: Detailed information on how to reach Sitges by train, from the city of Barcelona, or from the airports of Barcelona, can be obtained from the Spanish Railways official website.  Additional information regarding train transportation is available on the touristic website of Sitges.

Timetables for the green line R2 from El-Prat Airport to Sitges and back can also be found on the airport’s webpages.

By taxi: The distance to Stiges from Barcelona Airport is approximately 20 kmn.  This will take about 30 minutes in a taxi, costing from €65-€70.

By car: Depending on which airport you travel from, you can find very helpful guides to reach Sitges on the touristic website of Sitges.  This site also indicates the highway toll-charges.

Webinar

Please check out our webinar, Virtual Vaccine Technology: Focus on Covid-19, held originally on June 16, 2020. 

Program:

  • Introduction by Vaccine Technology VIII Chairs Francesc Gòdia, Charles Lutsch, Linda Hwee-Lin Lua, Tarit Mukhopadhyay 
  •  Julià Blanco, IRSI Caixa, Barcelona, Spain
    “Characteristics and mechanisms of action of SARS CoV-2: What do we know?”
  •  Jerome Kim, International Vaccine Institute, Seoul, South Korea
    “Test, track, isolate, and treat in South Korea”
  • Jim Robinson
    CEPI (Coalition for Epidemic Preparedness Innovations), Oslo, Norway
    “Considerations for Manufacturing for a  Pandemic”
  • Sylvie Briand
    WHO, Geneva, Switzerland
    “Covid-19: An unprecedented pandemic” 
  • Paul Young
    University of Queensland, Brisbane, Australia
    “Molecular Clamp Technology for Covid-19 vaccines”
  • Valérie Lecouturier
    Sanofi Pasteur, Marcy l’Etoile, France
    “Development of a subunit Covid-19 pandemic vaccine”
  • David Robinson
    Bill and Melinda Gates Foundation, Seattle, USA
    “Global response to current and future pandemics”
  • Recap and Future – Vaccine Technology VIII Conference Chairs 

Sponsors


Sponsor Packages

 Package A: $1,000 

• Name of Company on Sponsor List in Program 
• Company Logo displayed on screen between sessions 

Package B: $2,500 

• Half page ad in program 
• Name of Company on Sponsor List in Program 
• Company Logo displayed on screen between sessions 

Package C: $5,000 

• Full page ad in program 
• Sponsor a Coffee Break including poster display 
• Name of Company on Sponsor List in Program 
• Company logo and link on conference website 
• Company Logo displayed on screen between sessions 

Package D: $7,500 

• Sponsor a Scientific Session or Workshop including brief oral introduction 
• Full page ad in program 
• Name of Company on Sponsor List in Program 
• Company logo and link on conference website 
• Company Logo displayed on screen between sessions 

Package E: $10,000 

• Table of company information (*space limited) 
• Full page ad in program 
• Name of Company on Sponsor List in Program 
• Company logo and link on conference website 
• Company Logo displayed on screen between sessions 

Package F: $20,000 

• Table of company information (*space limited) 
• Company information packet available in attendees’ registration materials 
• Company logo and link on conference website 
• Full page ad in program 
• Company logo displayed on screen between sessions 
• Name of company on sponsor list in program 

Kevin Korpics (kevin@engconfintl.org) (+1-212-514-6760) may be contacted for invoicing and other questions. Please make checks payable to: 

Engineering Conferences International 
Attn: Vaccine Technology Conference 
32 Broadway, Suite 314 
New York, NY 10004 

Payment can also be made via wire transfer or credit card. 

General Information about ECI

Engineering Conferences International (ECI) is a not-for-profit, global engineering conferences program, originally established in 1962 that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.

The format of the conference provides morning and late afternoon or evening sessions in which major presentations are made. Poster sessions will be scheduled for evening discussion as well. Available time is included during the afternoons for ad hoc meetings, informal discussions, and/or recreation. This format is designed to enhance rapport among participants and promote dialogue on the development of the meeting. We believe the conferences have been instrumental in generating ideas and disseminating information to a greater extent than is possible through more conventional forums.

All participants are expected both to attend the entire conference and to contribute actively to the discussions. The recording/photographing of lectures and presentations is forbidden. As ECI conferences take place in an informal atmosphere, casual clothing is the usual attire.

Smoking is prohibited at ECI conferences and conference functions.